All patients
EGFR mutant EGFR mutation Ex19del EGFR mutation L858R EGFR wild type Gender, female Gender, male smoker (current or former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
metastatic/advanced NSCLC (mNSCLC) - 1st line (L1), ... vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results ARCHER 1050, 2017 (REV) 1.32 [1.01; 1.72]
CTONG 0901, 2017 (REV) 1.19 [0.89; 1.59]
H3E-CR-S131, 2016 (REV) 1.06 [0.77; 1.48]
IPASS (non smoker), 2012 0.97 [0.77; 1.22]
1.12 [0.97 ; 1.28 ] ARCHER 1050, 2017 (REV), CTONG 0901, 2017 (REV), H3E-CR-S131, 2016 (REV), IPASS (non smoker), 2012 4 4% 2,161 moderate not evaluable deaths (OS) (extension)detailed results ARCHER 1050, 2017 (REV) 1.34 [1.06; 1.69]
1.34 [1.06 ; 1.69 ] ARCHER 1050, 2017 (REV) 1 0% 452 NA not evaluable progression or deaths (PFS)detailed results ARCHER 1050, 2017 (REV) 1.69 [1.35; 2.13]
CTONG 0901, 2017 (REV) 1.23 [0.95; 1.61]
H3E-CR-S131, 2016 (REV) 1.18 [0.88; 1.58]
IPASS (non smoker), 2012 0.74 [0.65; 0.85]
1.15 [0.76 ; 1.75 ] ARCHER 1050, 2017 (REV), CTONG 0901, 2017 (REV), H3E-CR-S131, 2016 (REV), IPASS (non smoker), 2012 4 93% 2,161 moderate not evaluable DORdetailed results H3E-CR-S131, 2016 (REV) 1.19 [0.75; 1.88]
1.19 [0.75 ; 1.88 ] H3E-CR-S131, 2016 (REV) 1 0% 105 NA not evaluable objective responses (ORR)detailed results ARCHER 1050, 2017 (REV) 1.88 [1.17; 3.02]
CTONG 0901, 2017 (REV) 0.75 [0.46; 1.23]
H3E-CR-S131, 2016 (REV) 1.27 [0.76; 2.13]
IPASS (non smoker), 2012 1.59 [1.25; 2.02]
1.33 [0.94 ; 1.90 ] ARCHER 1050, 2017 (REV), CTONG 0901, 2017 (REV), H3E-CR-S131, 2016 (REV), IPASS (non smoker), 2012 4 66% 2,161 moderate not evaluable AE (any grade)detailed results ARCHER 1050, 2017 (REV) 0.24 [0.03; 2.19]
0.24 [0.03 ; 2.19 ] ARCHER 1050, 2017 (REV) 1 0% 451 NA not evaluable AE (grade 3-4)detailed results ARCHER 1050, 2017 (REV) 0.41 [0.28; 0.61]
0.41 [0.28 ; 0.61 ] ARCHER 1050, 2017 (REV) 1 0% 451 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results ARCHER 1050, 2017 (REV) 0.62 [0.37; 1.05]
0.62 [0.37 ; 1.05 ] ARCHER 1050, 2017 (REV) 1 0% 451 NA not evaluable TRAE leading to discontinuation (any grade)detailed results ARCHER 1050, 2017 (REV) 0.67 [0.34; 1.33]
0.67 [0.34 ; 1.33 ] ARCHER 1050, 2017 (REV) 1 0% 451 NA not evaluable 0.0 2.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-02 18:38 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 196,36,228,174,171,173,307,165,163,176,308,164,166,220
- treatments: 428
